Researchers at the University of North Carolina at Chapel Hill are studying innovative ways to promote healthy eating, physical activity, and weight loss in young adults using a smartphone app, digital health tools, and daily messaging. We are seeking volunteers to enroll in a 6-month research study that tests a smartphone-delivered weight loss program designed specifically for young adults.

The purpose of this research study is to explore benefits of workplace social connection following coffee meetups with colleagues. Must be a full-time UNC employee to participate.

Many students have beliefs about intelligence that can relate to their academic performance. Therefore, the purpose of this study is to investigate if the way students learn and adapt in the classroom varies as a function of their beliefs. Research on how beliefs influence student performance is sorely needed and of high priority.

The study purpose is to determine reaction time differences and intra-variability between the college-aged athletic population and the college-aged general population.

To get a number reading of a CD3+/CD8+ T cell Breast Immunoscore using immunofluorescence (QIF) in posttreatment FFPE tumor biopsy samples collected on day 14-21 of C1 of Pembrolizumab.

In this project, we want to work with community partners to develop a curriculum for developing and teaching racial literacy. The content will recognize the legacies of racism and draw on the rich community-based experiences of the Tar Heel Bus Tour.

The purpose of this study is to use an MRI and other devices to observe the brain and body activity that happens when people feel certain emotions.

Have you ever been diagnosed with metastatic triple negative breast cancer and received 2 or less lines of chemotherapy for your metastatic disease? If so you may be eligible for a trial to evaluate different treatment combination with avelumab for your metastatic breast cancer.

The purpose of this study is to evaluate a new treatment routine for patients with metastatic HER2 -positive breast cancer. We want to find out what effects, good and bad, using a Poly (ADP-Ribose) polymerase (PARP) inhibitor called niraparib in combination with trastuzumab has on patients with metastatic HER2- positive breast cancer.

Purpose: Is the combination of T-DM1 and a newer drug tucatinib, better than usual treatment with T-DM1 alone at preventing your cancer from returning? Treatment with T-DM1 and placebo or T-DM1 and tucatinib, for up to 14 cycles, unless the breast cancer returns or the side effects become too severe. If the breast cancer returns while on the study, the treatment will be changed. After completion of T-DM1 and/or placebo, or T-DM1 and tucatinib, the study doctor will continue to follow the patients condition with clinic visits every 6 months for 10 years and watch for side effects and for signs of breast cancer returning.